1 / 6

Chronic Hepatitis B (CHB) treatment

https://www.aligos.com/<br>Chronic Hepatitis B (CHB) treatment<br>Nonalcoholic Steatohepatitis (NASH) treatment<br>Hepatocellular Carcinoma (HCC) treatment<br>Nonalcoholic Steatohepatitis (NASH) solutions

osaligalig
Télécharger la présentation

Chronic Hepatitis B (CHB) treatment

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. aligos Chronic Hepatitis B (CHB) treatment Nonalcoholic Steatohepatitis (NASH) treatment Hepatocellular Carcinoma (HCC) treatment Nonalcoholic Steatohepatitis (NASH) solutions

  2. Chronic Hepatitis B (CHB) treatment Aligos is discovering and developing new classes of molecules that interact directly with disease-causing modalities such as viral encoded proteins and nucleic acids, as well as oncogenes and their resultant proteins in the case of our cancer indications. The company is also pursuing novel therapeutic agents aimed at activation of the patients immune system, to create lasting benefits for the diseases that cause significant morbidity and mortality.

  3. Nonalcoholic Steatohepatitis (NASH) solutions Chronic Hepatitis B (CHB) treatment Nonalcoholic Steatohepatitis (NASH) treatment Hepatocellular Carcinoma (HCC) treatment Nonalcoholic Steatohepatitis (NASH) solutions

  4. Hepatocellular Carcinoma (HCC) treatment Hepatocellular carcinoma (HCC) is the fifth most regular type of malignancy worldwide and the third most basic reason for disease related passings. HCC regularly happens out of sight of a cirrhotic liver[1]. Orthotopic liver transplantation (OLT) is a successful treatment for both HCC and hidden cirrhosis, and is viewed as the best helpful alternative. Sadly, most instances of HCC present in a propelled stage and are not appropriate possibility for OLT[2]. As of late reconnaissance procedures in patients at a higher danger of HCC have prompted the conclusion of the sickness at a lot prior stages. Patients in beginning times have an a lot higher possibility of therapeudic reaction with various treatment options[2,3]. Tumor organizing assumes a basic job in controlling the treatment choices, yet visualization is influenced by the seriousness of hidden liver brokenness. Various organizing frameworks are accessible for use in HCC, and there is no overall accord on a favored framework. The Child-Pugh characterization framework and the model for end-organize liver infection (MELD).

  5. About Us Aligos is discovering and developing new classes of molecules that interact directly with disease-causing modalities such as viral encoded proteins and nucleic acids, as well as oncogenes and their resultant proteins in the case of our cancer indications. The company is also pursuing novel therapeutic agents aimed at activation of the patients immune system, to create lasting benefits for the diseases that cause significant morbidity and mortality.

More Related